Solvent-based paclitaxel is a chemotherapy used to treat a number of cancers. A subset of patients is unable to tolerate paclitaxel because of the solvents used to improve its solubility1.
Apealea is a patented, water-soluble, intravenously-injectable formulation of paclitaxel, developed using Vivesto’s proprietary technology platform XR-17™. Apealea has undergone clinical development to, in combination with carboplatin, to treat adults with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
1Gelderblom et al. European Journal of Cancer 37 (2001)
